17. 多系統萎縮症 ［臨床試験数：51，薬物数：85（DrugBank：41），標的遺伝子数：57，標的パスウェイ数：98］
Searched query = "Multiple system atrophy", "Olivopontocerebellar atrophy", "Striatonigral degeneration", "Shy Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03753763 | September 9, 2019 | 28 October 2019 | Safinamide for Multiple System Atrophy (MSA) | 12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA | Multiple System Atrophy | Drug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placebo | Zambon SpA | Recruiting | 30 Years | 80 Years | All | 48 | Phase 2 | Italy;Spain | |
| 2 | NCT04004819 | August 15, 2019 | 30 September 2019 | Rituximab for Multiple System Atrphy | Rituximab Therapy for the Patients With Multiple Syetem Atrophy | Multiple System Atrophy | Drug: Rituximab | First Affiliated Hospital of Fujian Medical University | Recruiting | 18 Years | 80 Years | All | 50 | Phase 2 | China | |
| 3 | NCT03952806 | July 29, 2019 | 11 November 2019 | Study of BHV-3241 in Subjects With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy | Multiple System Atrophy | Drug: Verdiperstat;Drug: Placebo | Biohaven Pharmaceuticals, Inc. | Recruiting | 40 Years | 75 Years | All | 250 | Phase 3 | United States;Austria;France;Germany;Italy;United Kingdom | |
| 4 | JPRN-UMIN000036952 | 2019/06/04 | 16 July 2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan | |
| 5 | NCT03901638 | April 2, 2019 | 15 April 2019 | Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy | Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial | Ataxia, Cerebellar;Multiple System Atrophy | Drug: Tllsh2910;Drug: Placebo | National Taiwan University Hospital | Recruiting | 18 Years | 80 Years | All | 60 | Phase 3 | Taiwan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03589976 | September 1, 2018 | 14 October 2019 | A Futility Trial of Sirolimus in Multiple System Atrophy | A Single Center Randomized,Double Blind, Placebo-controlled Futility Trial to Determine if Sirolimus is of Sufficient Promise to Slow the Progression of Multiple System Atrophy | Multiple System Atrophy | Drug: Sirolimus 2 MG;Other: Placebo | NYU Langone Health | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 30 Years | 80 Years | All | 56 | Phase 2 | United States |
| 7 | NCT03403309 | May 2, 2018 | 15 July 2019 | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study) | Multiple System Atrophy | Drug: 1) Inosine 5'-monophosphate;Drug: Placebo | Yonsei University | Not recruiting | 19 Years | 75 Years | All | 43 | Phase 2 | Korea, Republic of | |
| 8 | NCT03265444 | April 13, 2018 | 11 June 2018 | Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy | A Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Multiple System Atrophy | Multiple System Atrophy | Biological: CS10BR05 | Corestem, Inc. | Recruiting | 30 Years | 75 Years | All | 9 | Phase 1 | Korea, Republic of | |
| 9 | NCT03446807 | April 2018 | 11 June 2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 10 | NCT03174938 | May 15, 2017 | 11 June 2018 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02897063 | September 2016 | 25 February 2019 | Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure | The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 | Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension | Drug: Droxidopa;Drug: Midodrine;Drug: Placebo | Vanderbilt University Medical Center | Recruiting | 40 Years | 80 Years | All | 34 | Phase 1 | United States | |
| 12 | NCT02705755 | May 2016 | 7 October 2019 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension | Drug: TD-9855;Drug: Placebo | Theravance Biopharma | Not recruiting | 40 Years | N/A | All | 34 | Phase 2 | United States | |
| 13 | NCT02726711 | April 2016 | 25 February 2019 | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 | Multiple System Atrophy;Orthostatic Hypotension;Supine Hypertension | Drug: Trimethaphan;Drug: Placebo | Vanderbilt University | Recruiting | 40 Years | 80 Years | All | 32 | Phase 1 | United States | |
| 14 | NCT02994719 | March 1, 2016 | 18 December 2018 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | Recruiting | 18 Years | 85 Years | All | 110 | N/A | United States | |
| 15 | NCT02591173 | February 2016 | 26 August 2019 | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Autonomic Nervous System Disorders;Pure Autonomic Failure;Shy-Drager Syndrome;Orthostatic Hypotension, Dysautonomic | Drug: Angiotensin-(1-7);Drug: Saline | Vanderbilt University Medical Center | Recruiting | 18 Years | 80 Years | All | 22 | Early Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02388295 | April 27, 2015 | 16 December 2017 | AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy | Multiple System Atrophy, MSA | Drug: AZD3241;Drug: Placebo | AstraZeneca | Not recruiting | 30 Years | 80 Years | All | 59 | Phase 2 | United States;Austria;Finland;France;Italy;Sweden;United Kingdom | |
| 17 | EUCTR2014-004902-13-GB | 09/04/2015 | 7 December 2015 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1 Level: PT Classification code 10064060 Term: Multiple system atrophy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Not available CAS Number: 890655-80-8 Current Sponsor code: AZD3241 Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AZD3241 300mg Product Code: AZD3241 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Not available CAS Number: 890655-80-8 Current Sponsor code: AZD3241 Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | AstraZeneca AB | Authorised | Female: yes Male: yes | 64 | United States;Finland;United Kingdom;Sweden | ||||
| 18 | NCT02429557 | April 2015 | 25 February 2019 | Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure | Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure | Orthostatic Hypotension;Pure Autonomic Failure;Multiple System Atrophy;Autonomic Failure | Other: Abdominal compression;Other: Sham abdominal compression;Drug: Placebo pill;Drug: midodrine | Vanderbilt University | Recruiting | 18 Years | 80 Years | All | 20 | Phase 1 | United States | |
| 19 | NCT02270489 | December 11, 2014 | 16 December 2017 | Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA | A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy | Multiple System Atrophy;Neurodegenerative Diseases | Biological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component | Affiris AG | University Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Forschungszentrum Juelich;University Hospital, Toulouse | Not recruiting | 30 Years | 75 Years | All | 30 | Phase 1 | France |
| 20 | NCT02149901 | October 2014 | 15 April 2019 | Water and Sudafed in Autonomic Failure | Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure | Shy-Drager Syndrome;Multiple System Atrophy | Drug: Pseudoephedrine + 480 ml water;Drug: Pseudoephedrine + 50 ml water;Other: Placebo + 480 ml water (optional);Other: Placebo + 50 ml water (optional) | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS) | Not recruiting | 18 Years | 80 Years | All | 35 | Early Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2012-005539-10-DE | 29/04/2014 | 2 October 2017 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use Trade Name: Xeomin Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: NT 101 CAS Number: 93384-43-1 Current Sponsor code: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intraglandular use | Merz Pharmaceuticals GmbH | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | |||
| 22 | NCT02064166 | February 2014 | 3 December 2018 | Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. | A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy | Parkinson Disease;Multiple System Atrophy | Drug: Intranasal Insulin | Peter Novak | Not recruiting | 18 Years | N/A | All | 15 | Phase 2 | United States | |
| 23 | NCT02071459 | February 2014 | 16 December 2017 | Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA | Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo | Multiple System Atrophy | Drug: L-Threo DOPS;Drug: placebo | University Hospital, Toulouse | Recruiting | 30 Years | 80 Years | All | 108 | Phase 2/Phase 3 | France | |
| 24 | EUCTR2012-000928-18-DE | 21/11/2013 | 5 December 2016 | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach | Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sunphenon EGCg Pharmaceutical Form: Capsule, hard INN or Proposed INN: EGCG CAS Number: 989-51-5 Current Sponsor code: EGCG Other descriptive name: GREEN TEA LEAF Concentration unit: mg milligram(s) Concentration type: range Concentration number: 800-1200 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Hospital of the Ludwig-Maximilians-University of Munich | Not Recruiting | Female: yes Male: yes | 86 | Phase 3 | Germany | |||
| 25 | JPRN-UMIN000011111 | 2013/07/16 | 2 April 2019 | Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | JPRN-UMIN000010712 | 2013/05/20 | 2 April 2019 | Ubiquinol for patients with multiple system atrophy | Patients with multiple system atrophy | Patients with administration of ubiquinol | Department of Neurology, the University of Tokyo Hospital | Not Recruiting | 30years-old | 80years-old | Male and Female | 1 | Not selected | Japan | ||
| 27 | JPRN-UMIN000008959 | 2012/11/01 | 2 April 2019 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Multiple system atrophy(MSA) Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | Not Recruiting | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan | ||
| 28 | NCT02315027 | October 2012 | 14 October 2019 | Mesenchymal Stem Cell Therapy in Multiple System Atrophy | Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History | MSA | Biological: autologous mesenchymal stem cells | Mayo Clinic | Not recruiting | 30 Years | 80 Years | All | 30 | Phase 1 | United States | |
| 29 | NCT01577992 | December 2011 | 19 February 2015 | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Pain Threshold;Multiple System Atrophy | Drug: Levodopa test;Procedure: determination of objective and subjective pain threshold | University Hospital, Toulouse | Fondation de France | Not recruiting | 50 Years | 80 Years | Both | 42 | N/A | France |
| 30 | NCT01287221 | March 2011 | 19 October 2017 | Study of Rifampicin in Multiple System Atrophy | Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy | Multiple System Atrophy | Drug: Rifampicin;Drug: placebo | Phillip Low | National Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease Research Network Autonomic Consortium | Not recruiting | 30 Years | 80 Years | All | 100 | Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01292694 | March 2011 | 3 September 2018 | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Losartan;Drug: Captopril;Drug: Placebo | Vanderbilt University | Not recruiting | 18 Years | 85 Years | All | 12 | Phase 1 | United States | |
| 32 | EUCTR2009-018157-23-GB | 30/11/2010 | 19 March 2012 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | Multiple system atrophy MedDRA version: 12.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Pharmaceutical Form: Tablet Current Sponsor code: AZD3241 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: AZD3241 Product Code: AZD3241 Pharmaceutical Form: Tablet Current Sponsor code: AZD3241 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | AstraZeneca AB | Not Recruiting | Female: yes Male: yes | 135 | Phase 2a | United Kingdom;Spain;Austria | |||
| 33 | NCT01119417 | May 2010 | 25 February 2019 | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: BQ123;Drug: Bq123;Drug: Saline | Vanderbilt University | Recruiting | 18 Years | 85 Years | All | 12 | Phase 1 | United States | |
| 34 | NCT01136213 | April 2010 | 16 December 2017 | Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study | Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study | Multiple System Atrophy | Radiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / Placebo | University Hospital, Bordeaux | Not recruiting | 30 Years | 80 Years | All | 53 | N/A | France | |
| 35 | NCT01044693 | January 2010 | 19 October 2017 | Nebivolol in the Supine Hypertension of Autonomic Failure | Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg | Vanderbilt University | Forest Laboratories | Not recruiting | 18 Years | 80 Years | All | 20 | N/A | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2009-014644-11-DE | 08/12/2009 | 22 October 2012 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0 Level: PT Classification code 10064060 Term: Multiple system atrophy | Trade Name: AZILECT Pharmaceutical Form: Tablet INN or Proposed INN: Rasagiline CAS Number: 161735-79-1 Current Sponsor code: TVP-1012 Other descriptive name: Rasagiline mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Teva Pharmaceutical Industries Ltd | Not Recruiting | Female: yes Male: yes | 140 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | ||||
| 37 | NCT00997672 | October 2009 | 19 October 2017 | Lithium in Multiple System Atrophy | A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy. | Multiple System Atrophy | Drug: Lithium Carbonate;Drug: Placebo | Federico II University | Not recruiting | 18 Years | 80 Years | All | 10 | Phase 2 | Italy | |
| 38 | NCT00758849 | September 2008 | 19 February 2015 | Fipamezole in Neurogenic Orthostatic Hypotension | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease | Symptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System Atrophy | Drug: Placebo;Drug: Fipamezole | Juvantia Pharma Ltd | Santhera Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 24 | Phase 2 | France;Portugal |
| 39 | NCT00750867 | June 2008 | 16 December 2017 | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Multiple System Atrophy | Drug: intravenous immunoglobulin (IVIg) | University of Massachusetts, Worcester | Not recruiting | 18 Years | N/A | All | 9 | Phase 2 | United States | |
| 40 | NCT00822913 | June 2008 | 19 February 2015 | Botulinum A Toxin in Patients With Parkinson's Disease | The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. | Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity | Drug: Intravesical injection of Botulinum A toxin | University Of Perugia | University of Roma La Sapienza | Recruiting | 18 Years | 80 Years | Both | 20 | Phase 4 | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2007-004890-24-FR | 07/05/2008 | 19 March 2012 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: Fipamezole hydrochloride CAS Number: 150586-72-4 Current Sponsor code: JP-1730 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Sublingual use | Juvantia Pharma Ltd | Authorised | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | |||
| 42 | NCT00911365 | May 2008 | 19 February 2015 | Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | Multiple System Atrophy | Biological: autologous mesenchymal stem cells;Biological: normal saline | Yonsei University | Not recruiting | N/A | 75 Years | Both | 27 | Phase 2 | Korea, Republic of | |
| 43 | NCT01146548 | May 2008 | 7 April 2015 | Fluoxetine in Multiple System Atrophy Patients | Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial | Multiple System Atrophy | Drug: FLUOXETINE | University Hospital, Toulouse | Clinical Research Center, Toulouse | Not recruiting | 30 Years | 80 Years | Both | 87 | Phase 2 | France |
| 44 | EUCTR2007-004922-26-FR | 12/02/2008 | 19 March 2012 | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | atrophie multisystématisée MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy | Trade Name: PROZAC Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | CHU Toulouse | Authorised | Female: yes Male: yes | France | |||||
| 45 | NCT00738062 | January 2008 | 19 October 2017 | Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase Deficiency | Drug: Droxidopa;Drug: Placebo | Chelsea Therapeutics | Not recruiting | 18 Years | N/A | All | 103 | Phase 3 | United States;Australia;Canada;New Zealand | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00547911 | October 2007 | 19 October 2017 | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone | Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases | Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 14 | Phase 1/Phase 2 | United States | |
| 47 | NCT00103597 | January 2005 | 19 February 2015 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | Not recruiting | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia | |
| 48 | NCT00179023 | April 2003 | 12 March 2018 | The Autonomic Nervous System and Obesity | The Autonomic Nervous System and Obesity | OBESITY;HYPERTENSION;PURE AUTONOMIC FAILURE;SHY-DRAGER SYNDROME | Drug: Trimethaphan;Drug: Pseudoephedrine | Vanderbilt University | Not recruiting | 18 Years | 80 Years | All | 128 | Phase 1 | United States | |
| 49 | NCT01044992 | May 2002 | 19 February 2015 | Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study | Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge | Multisystemic Atrophy | Radiation: H215O PET;Drug: Levodopa | University Hospital, Toulouse | Not recruiting | 40 Years | 75 Years | Both | 38 | N/A | France | |
| 50 | NCT00211224 | April 2000 | 19 February 2015 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Not recruiting | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT00004478 | March 1999 | 19 February 2015 | Droxidopa in Treating Patients With Neurogenic Hypotension | Study of Droxidopa in Patients With Neurologic Hypotension | Shy-Drager Syndrome;Orthostatic Hypotension | Drug: droxidopa | Mount Sinai School of Medicine | Not recruiting | 20 Years | N/A | Both | N/A | United States |